Fig. 4. The botulinum toxin type A (BTX-A) inhibited the overexpression of CXCL13, CXCR5, and GAT-1 in chronic constriction injury (CCI) rats, and the effect of BTX-A is dose-dependent. The BTX-A reversed the increased expression of CXCL13, CXCR5, and GAT-1 induced by CCI in the spinal cord tested by western blot (A, E, I, M), DRG (B, F, J, N), sciatic nerve (C, G, K, O), and plantar skin (D, H, L, P). CXCL13: chemokine ligand 13, CXCR5: C-X-C chemokine receptor type 5, GAT-1: GABA transporter 1, DRG: dorsal root ganglia. The error bar means mean ± standard deviation. aP < 0.05 vs. sham group, bP < 0.05 vs. CCI + normal saline group, cP < 0.05 vs. CCI + 4 U/kg BTX-A group, dP < 0.05 vs. CCI + 10 U/kg BTX-A group; One-way ANOVA; n = 3 in each group.
© Korean J Pain
